Fig. 1From: MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosisSchedule of enrolment, interventions, and assessments of the MESEMS trial. *Optional studies as per sites desire; §MRI at week 0 and week 24 must be performed before the IV treatment with MSC or placeboBack to article page